



## **Efficacy and Safety of Atorvastatin for Chronic Subdural Hematoma: An Updated Systematic Review and Meta-Analysis**

*Almeida Monteiro Gde, et al. World Neurosurg. 2024; 188: 174-184*

- Chronic subdural hematoma (CSDH) is a prevalent neurological disorder that is frequently brought on by head trauma, particularly in the older population.
- Atorvastatin has shown the potential in improving patient outcomes by lowering hematoma volume of patients with CSDH and the present meta-analysis (7 studies, 1192 patients) was conducted to evaluate the efficacy efficacy of Atorvastatin for the same.
- Atorvastatin was observed to significantly ( $p=0.009$ ) reduce the recurrence rate of CSDH.
- Its benefits were also sustained in the subgroup analysis of patients who underwent initial conservative therapy.

**Atorvastatin might be beneficial in reducing CSDH recurrence, especially in patients receiving conservative treatment.**

